Date: 2018-06-05
Type of information: Development agreement
Compound: therapeutic antibodies targeting undisclosed targets
Company: Iontas (UK) LG Chem (South Korea)
Therapeutic area: Cancer - Oncology
Type agreement: collaboration - research - development
Action mechanism: monoclonal antibody
Disease:
Details:
- • On June 5, 2018, Iontas announced it has signed a collaboration agreement with Korean-based LG Chem for the discovery of therapeutic antibodies targeting undisclosed targets for use in the treatment of cancers. Under the agreement Iontas will use its proprietary antibody discovery platforms to deliver antibodies against biological targets selected by LG Chem and to further prove the biological activity of the antibodies.
Financial terms:
Latest news:
Is general: Yes
